Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERICA: Eribulin and Capecitabine Sequence in HER2-negative MBC
NCT05833919Phase 2Unknown
- Sponsor
- Consorzio Oncotech
- Start
- Jul 2018
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin in breast cancer, sponsored by Consorzio Oncotech. Status: unknown.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05833919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05833919.